VEGF blockade decelerates the growth of a murine experimental osteosarcoma

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 253-259

  Yin, Dezhen ^a,b   Jia, Tanghong ^a   Gong, Weiming ^a   Yu, Haiying ^b   Wooley, Paul H ^b   Mott, Michael P ^b   Yang, Shang You ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene transfer; Mouse model; Osteosarcoma; sFlt 1; VEGF blockage

Indexed keywords

BETA GALACTOSIDASE; MYC PROTEIN; PROTEIN C FOS; RETROVIRUS VECTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE EROSION; CANCER GENE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSDUCTION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMANS; LAC OPERON; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 48749121296     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000004     Document Type: Article

References (40)

1. Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ Jr and Murphy ML: High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer 33: 1151-1163, 1974.
2. Brower V: Tumor angiogenesis-new drugs on the block. Nat Biotechnol 17: 963-968, 1999.
3. Kong HL, Hecht D, Song W, Kovesdi I, Hackett NR, Yayon A and Crystal RG: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9: 823-833, 1998.
4. Millauer B, Shawver LK, Plate KH, Risau W and Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994.
5. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
6. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
7. Yanase T, Tamura M, Fujita K, Kodama S and Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53: 2566-2570, 1993.
8. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP and Ramakrishnan S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60: 2190-2196, 2000.
9. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
10. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
11. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992.
12. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
13. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
14. Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
15. Lee YH, Tokunaga T, Oshika Y, et al: Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35: 1089-1093, 1999.
16. Kaya M, Wada T, Akatsuka T, et al: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577, 2000.
17. Yang SY, Yu HY, Jeffrey E, et al: High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma 2007: 95628 (7 pages), 2007.
18. Kendall RL and Thomas KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993.
19. Kendall RL, Wang G and Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328, 1996.
20. Takayama K, Ueno H, Nakanishi Y, et al: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60: 2169-2177, 2000.
21. Yoshimura I, Mizuguchi Y, Miyajima A, Asano T, Tadakuma T and Hayakawa M: Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J Urol 171: 2467-2470, 2004.
22. Sako A, Kitayama J, Koyama H, Ueno H, Uchida H, Hamada H and Nagawa H: Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res 64: 3624-3628, 2004.
23. Graepler F, Verbeek B, Graeter T, et al: Combined endostatin/ sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 41: 879-886, 2005.
24. Schmidt K, Hoffend J, Altmann A, et al: Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin Cancer Res 11: 2132-2140, 2005.
25. Ye C, Feng C, Wang S, et al: sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 145: 817-822, 2004.
26. Mahasreshti PJ, Navarro JG, Kataram M, et al: Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 7: 2057-2066, 2001.
27. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J and Huard J: Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110: 751-759, 2002.
28. Yang S, Wu B, Mayton L, Evans CH, Robbins PD and Wooley PH: IL-1Ra and vIL-10 gene transfer using retroviral vectors ameliorates particle-associated inflammation in the murine air pouch model. Inflamm Res 51: 342-350, 2002.
29. Sud S, Yang SY, Evans CH, Robbins PD and Wooley PH: Effects of cytokine gene therapy on particulate-induced inflammation in the murine air pouch. Inflammation 25: 361-372, 2001.
30. Attia MA and Weiss DW: Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26: 1787-1800, 1966.
31. Yang SY, Wu B, Mayton L, Mukherjee P, Robbins PD, Evans CH and Wooley PH: Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis. Gene Ther 11: 483-491, 2004.
32. PE Applied Biosystems: TagMan Cytokine Gene Expression Plate I; Protocol. Anonymous. P/N 4304671, 37-53, 1998.
33. Ben-Josef E, Yang SY, Ji TH, et al: Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 161: 970-976, 1999.
34. Mahasreshti PJ, Kataram M, Wang MH, et al: Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 9: 2701-2710, 2003.
35. Barrios C, Castresana JS, Ruiz J and Kreicbergs A: Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. J Orthop Res 11: 556-563, 1993.
36. Gamberi G, Benassi MS, Bohling T, et al: C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55: 556-563, 1998.
37. Pompetti F, Rizzo P, Simon RM, et al: Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63: 37-50, 1996.
38. Van den BS, Rahmsdorf HJ, Herrlich P and Kaina B: Over-expression of c-fos increases recombination frequency in human osteosarcoma cells. Carcinogenesis 14: 925-928, 1993.
39. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW and Mercola D: The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5: 989-1000, 1990.
40. Cole MD and McMahon SB: The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18: 2916-2924, 1999.